Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation reports company developments tied to immune-driven diagnostics and immune medicine. The commercial-stage biotechnology company applies a proprietary platform to translate adaptive immune system genetics into clinical products, with operating activity organized around Minimal Residual Disease (MRD) and Immune Medicine.
Recurring updates for ADPT include clonoSEQ MRD testing adoption, MRD revenue trends, pharma regulatory milestone revenue, operating expense guidance, and quarterly financial results. Company news also covers immune receptor and TCR-antigen data partnerships, autoimmune and cancer-related research applications, investor conference participation, and management commentary on the company’s diagnostic and drug-development collaborations.
Adaptive Biotechnologies (Nasdaq: ADPT) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026. Management will host a conference call and webcast beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors website and the webcast will be archived for replay within 24 hours.
Investors can listen via the company website at www.adaptivebiotech.com and should check the Investors section for the live link and replay.
Adaptive Biotechnologies (Nasdaq: ADPT) reported preliminary, unaudited fourth quarter and full year 2025 results. Total revenue was approximately $72M in Q4 and $277M for FY2025, up 51% and 55% year‑over‑year. MRD revenue was about $62M in Q4 and $212M for the year, up 54% and 46% versus 2024; excluding an MRD regulatory milestone, MRD revenue grew 45% FY‑over‑FY. clonoSEQ tests delivered totaled ~30,000 in Q4 (+43%) and ~105,600 for the year (+39%). Cash and marketable securities were ~$227M at year end. Full audited results will be released during the February 2026 earnings call.
Adaptive Biotechnologies (Nasdaq: ADPT) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management is scheduled to present on Monday, January 12, 2026 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast will be available on the company’s Investors website at www.adaptivebiotech.com.
Adaptive Biotechnologies (NASDAQ: ADPT) announced two non-exclusive agreements with Pfizer on Dec 15, 2025: a target discovery collaboration to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis (RA) using Pfizer clinical samples, and a data licensing deal giving Pfizer access to Adaptive’s TCR-antigen datasets for AI/ML model training across immunology programs.
Adaptive will lead RA target discovery while Pfizer handles development and commercialization. Adaptive will receive an upfront payment and may earn additional milestone and licensing fees, with RA-related milestones potentially totaling about $890 million; specific financial terms are not disclosed.
Adaptive Biotechnologies (Nasdaq: ADPT) announced that Dr. Harlan Robins, Chief Scientific Officer and Co‑Founder, and Susan Bobulsky, Chief Commercial Officer, MRD, will participate in a Jefferies fireside chat on Minimal Residual Disease (MRD) in hematology/oncology with a deep dive into the clonoSEQ assay technology.
The session is scheduled for Thursday, December 11, 2025, 2:00 p.m. to 3:00 p.m. ET. Interested parties may contact their Jefferies sales representative for participation details.
Adaptive Biotechnologies (Nasdaq: ADPT) announced expanded clinical use of its clonoSEQ measurable residual disease (MRD) test at the 67th ASH Annual Meeting, Dec 6–9, 2025 in Orlando.
Key highlights: 90 abstracts feature clonoSEQ data, including 17 showing MRD-guided clinical interventions. The phase II EndRAD study reported that 51 NGS MRD-negative B-ALL patients receiving non-TBI transplant conditioning had outstanding event-free and overall survival comparable to standard TBI approaches. Additional data include 200-patient AURIGA MRD dynamics, intensified maintenance doubling MRD-negativity, and an 80-patient CLL cohort showing deep remissions at a 10^-6 MRD threshold.
Adaptive Biotechnologies (Nasdaq: ADPT) announced that its next-generation sequencing clonoSEQ® MRD test is featured in 89 abstracts, including 36 oral presentations, at the 67th ASH Annual Meeting scheduled for Dec. 6–9, 2025 in Orlando.
Abstracts cover multiple myeloma, ALL, CLL, MCL, DLBCL and other blood cancers, with more than 17 presentations showing clonoSEQ informing real-world treatment decisions and expanded use in clinical trials across modalities such as CAR T and bispecific antibodies.
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in late 2025: a presentation at the Jefferies Global Healthcare Conference in London on November 19, 2025 at 8:00 a.m. GMT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 8:30 a.m. ET.
Interested parties may access live and archived webcasts on the company’s Investors section at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) reported third quarter 2025 results on November 5, 2025, showing strong MRD momentum and updated guidance.
Key points: Q3 revenue $94.0M (includes $33.7M one-time Genentech amortization); excluding Genentech $60.2M (+40% YoY). MRD revenue $56.8M (+52% YoY) with clonoSEQ volume 27,111 (+38% YoY). MRD achieved cash flow positivity and an MRD Adjusted EBITDA of $7.0M. Company Adjusted EBITDA was $28.0M. Cash and marketable securities were $216.8M. Company raised full-year MRD guidance to $202–$207M and narrowed operating spend and cash burn guidance.
Adaptive Biotechnologies (Nasdaq: ADPT) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors web page at www.adaptivebiotech.com, and the webcast will be archived and available for replay within 24 hours.